Report cover image

Global Age-related Macular Degeneration (AMD) Drugs Market Size Study, by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), by Molecule (Ranibizumab, Aflibercept, Faricimab), by Approval Type (Biologic, Biosimilar), by Type of AMD, and Regional Fore

Publisher Factview Research
Published Jun 27, 2025
Length 285 Pages
SKU # FAVR20179459

Description

The Global Age-related Macular Degeneration (AMD) Drugs Market is currently valued at approximately USD 10.4 billion in 2024 and is forecasted to grow at (CAGR) of 10.40% over the forecast period from 2024 to 2034. Age-related macular degeneration, a leading cause of vision impairment in aging populations worldwide, has propelled significant innovations in pharmacological interventions. Advanced treatments, such as biologics and biosimilars, are shaping a new era of therapeutic efficacy, focusing on slowing disease progression and improving patients' quality of life.

Pharmaceutical advancements like Lucentis, Eylea HD, and the novel Syfovre, alongside emerging biosimilars, are fueling the market's growth trajectory. The rise in patient awareness about early intervention and increasing healthcare expenditure in ophthalmology further amplify the demand for AMD therapies. Notably, the integration of personalized medicine into treatment protocols is a defining trend, offering tailored solutions that optimize therapeutic outcomes while minimizing adverse effects. Despite these advances, the high cost of biologic drugs and regulatory complexities surrounding biosimilar approvals may pose challenges to market participants during the forecast period.

Regionally, the AMD drugs market exhibits diverse growth dynamics. North America commands the largest market share, underpinned by robust healthcare infrastructure, high prevalence of AMD, and substantial investment in R&D initiatives. Europe follows closely, driven by strong government support and the adoption of advanced biologics. Meanwhile, the Asia-Pacific region is expected to record the fastest growth, attributed to increasing healthcare investments, rising geriatric populations, and enhanced access to ophthalmic care across emerging economies like China and India.

Major market players included in this report are:

1. Regeneron Pharmaceuticals, Inc.

2. Roche Holding AG

3. Novartis AG

4. Bayer AG

5. Biogen Inc.

6. Alimera Sciences

7. Adverum Biotechnologies, Inc.

8. Eyepoint Pharmaceuticals

9. Outlook Therapeutics, Inc.

10. Apellis Pharmaceuticals, Inc.

11. Amgen Inc.

12. Pfizer Inc.

13. Samsung Bioepis

14. Intas Pharmaceuticals

15. Santen Pharmaceutical Co., Ltd.

The detailed segments and sub-segments of the market are explained below:

By Product:
  • Lucentis
  • Eylea & Eylea HD
  • Vabysmo
  • Syfovre
By Molecule:
  • Ranibizumab
  • Aflibercept
  • Faricimab
By Approval Type:
  • Biologic
  • Biosimilar
By Type of AMD:
  • Wet AMD
  • Dry AMD
By Region:

North America
  • U.S.
  • Canada
Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa
Years considered for the study are as follows:
  • Historical year – 2022
  • Base year – 2024
  • Forecast period – 2024 to 2034
Key Takeaways:
  • Comprehensive revenue analysis and forecasts for a 10-year period (2022–2032).
  • Detailed segmentation and regional insights for North America, Europe, APAC, Latin America, and MEA.
  • Competitive landscape profiling major industry players with strategic recommendations for market expansion.
  • Examination of emerging trends like biosimilar approvals and personalized medicine applications.
  • Demand-side and supply-side assessments to identify growth opportunities and market challenges.

Table of Contents

285 Pages
Chapter 1. Global Age-related Macular Degeneration (AMD) Drugs Market Executive Summary
1.1. Global AMD Drugs Market Size & Forecast (2024-2034)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Molecule
1.3.3. By Approval Type
1.3.4. By Type of AMD
1.4. Key Trends
1.5. Recession Impact
1.6. Investment Analysis
1.7. Investment Rationale
1.8. Analyst Recommendation & Conclusion
Chapter 2. Global AMD Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global AMD Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Increasing Prevalence of AMD
3.1.2. Advancements in Biologic and Biosimilar Therapies
3.1.3. Rising Healthcare Expenditure in Ophthalmology
3.2. Market Challenges
3.2.1. High Cost of Biologic Drugs
3.2.2. Regulatory Complexities Surrounding Biosimilars
3.3. Market Opportunities
3.3.1. Growth in Personalized Medicine
3.3.2. Rising Patient Awareness and Early Intervention
3.3.3. Expansion in Emerging Markets
Chapter 4. Global AMD Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global AMD Drugs Market Size & Forecasts by Product 2024-2034
5.1. Segment Dashboard
5.2. Global AMD Drugs Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Lucentis
5.2.2. Eylea & Eylea HD
5.2.3. Vabysmo
5.2.4. Syfovre
Chapter 6. Global AMD Drugs Market Size & Forecasts by Molecule 2024-2034
6.1. Segment Dashboard
6.2. Global AMD Drugs Market: Molecule Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.2.1. Ranibizumab
6.2.2. Aflibercept
6.2.3. Faricimab
Chapter 7. Global AMD Drugs Market Size & Forecasts by Approval Type 2024-2034
7.1. Segment Dashboard
7.2. Global AMD Drugs Market: Approval Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.2.1. Biologic
7.2.2. Biosimilar
Chapter 8. Global AMD Drugs Market Size & Forecasts by Type of AMD 2024-2034
8.1. Segment Dashboard
8.2. Global AMD Drugs Market: Type of AMD Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
8.2.1. Wet AMD
8.2.2. Dry AMD
Chapter 9. Global AMD Drugs Market Size & Forecasts by Region 2024-2034
9.1. North America AMD Drugs Market
9.1.1. U.S. AMD Drugs Market
9.1.1.1. Product Breakdown Size & Forecasts, 2024-2034
9.1.1.2. Molecule Breakdown Size & Forecasts, 2024-2034
9.1.2. Canada AMD Drugs Market
9.2. Europe AMD Drugs Market
9.2.1. UK AMD Drugs Market
9.2.2. Germany AMD Drugs Market
9.2.3. France AMD Drugs Market
9.2.4. Spain AMD Drugs Market
9.2.5. Italy AMD Drugs Market
9.2.6. Rest of Europe AMD Drugs Market
9.3. Asia-Pacific AMD Drugs Market
9.3.1. China AMD Drugs Market
9.3.2. India AMD Drugs Market
9.3.3. Japan AMD Drugs Market
9.3.4. Australia AMD Drugs Market
9.3.5. South Korea AMD Drugs Market
9.3.6. Rest of Asia Pacific AMD Drugs Market
9.4. Latin America AMD Drugs Market
9.4.1. Brazil AMD Drugs Market
9.4.2. Mexico AMD Drugs Market
9.4.3. Rest of Latin America AMD Drugs Market
9.5. Middle East & Africa AMD Drugs Market
9.5.1. Saudi Arabia AMD Drugs Market
9.5.2. South Africa AMD Drugs Market
9.5.3. Rest of Middle East & Africa AMD Drugs Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Regeneron Pharmaceuticals, Inc.
10.1.2. Roche Holding AG
10.1.3. Novartis AG
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Regeneron Pharmaceuticals, Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Bayer AG
10.3.3. Biogen Inc.
10.3.4. Alimera Sciences
10.3.5. Adverum Biotechnologies, Inc.
10.3.6. Eyepoint Pharmaceuticals
10.3.7. Outlook Therapeutics, Inc.
10.3.8. Apellis Pharmaceuticals, Inc.
10.3.9. Amgen Inc.
10.3.10. Pfizer Inc.
10.3.11. Samsung Bioepis
10.3.12. Intas Pharmaceuticals
10.3.13. Santen Pharmaceutical Co., Ltd.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us